Food Allergy Challenge Diagnostic Study

Status Completed

Clinical Trial Summary

The objective of this study is to correlate various diagnostic measurements taken during an escalating dose oral food challenge to the subject's response. This study will investigate whether non invasive objective biomarkers can indicate a positive response to an escalating dose OFC before a systemic reaction occurs.

Clinical Trial Description

Patients often discover their food allergies after consuming a given food and experiencing a subsequent allergic reaction. The majority of patients (75%) will then consult a food allergist for formal diagnosis and treatment information. With respect to patient quality of life, there is tremendous benefit in having a confirmed diagnosis of food allergy as often patients are unsure of the source of their reaction outside the office. Allergists will conduct a Skin Prick Test (SPT) and assess serum specific IgE levels to screen for specific food protein sensitivities. However, a positive response in SPT and specific IgE will confirm only sensitivity, and in more than 70% of cases patients that respond positively to SPT and specific IgE testing will NOT manifest an allergic response to food consumption. To address this issue, most food allergists will recommend an oral food challenge in a controlled setting to confirm the allergic response from consuming the suspected foods. The oral food challenge (OFC) consists of consuming escalating levels of the suspect food, (usually mixed in applesauce or controlled baked goods), until either a reaction manifests or until the challenge is complete with no reaction. The food challenge process poses significant risk to the patient. In 5% of cases, the patient experiences a severe allergic response which requires the use of epinephrine. These responses typically consist of severe reactions in GI or respiratory and arise from challenging patients with higher doses of food allergen then is necessary to prove a mild allergic response, which is directly linked to variability in diagnosis of a positive response, within subjects and within investigators.

The investigators hypothesize that measurements taken using minimally-invasive diagnostic tests during the course of an escalating-dose oral food challenge will be able to detect a positive response before a systemic reaction occurs in the patient and may be able to screen with individuals predisposed to EOE. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02606721
Study type	Observational
Source	ORA, Inc.
Contact
Status	Completed
Phase
Start date	March 2016
Completion date	October 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01904604` - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial	Phase 2
Enrolling by invitation	`NCT04885959` - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development	N/A
Recruiting	`NCT03974555` - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT01420705` - Bacille Calmette-Guérin (BCG) Vaccine and Atopy	N/A
Completed	`NCT00850668` - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults	Phase 1
Withdrawn	`NCT00736112` - Food Allergy - Tubes - Adenoids (FATA) Trial	N/A
Active, not recruiting	`NCT00298337` - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008	Phase 2/Phase 3
Completed	`NCT03693456` - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response	N/A
Completed	`NCT00461097` - Oral Immunotherapy for Childhood Egg Allergy	Phase 2
Active, not recruiting	`NCT02457416` - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut	N/A
Completed	`NCT02825069` - Study on the Induction of Food Tolerance in Babies	N/A
Completed	`NCT02350660` - Oral Immunotherapy for Peanut and Mammalian Meat Allergies	N/A
Completed	`NCT01084174` - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy	Phase 1/Phase 2
Completed	`NCT00597675` - Oral Immunotherapy for Peanut Allergy (PMIT)	Phase 2
Completed	`NCT00932828` - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study	Phase 2
Completed	`NCT01373242` - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance	Phase 1/Phase 2
Completed	`NCT00578656` - An Interventional Study of Milk Allergy	Phase 0
Completed	`NCT00356174` - An Observational Study of Childhood Food Allergy	N/A
Completed	`NCT02304991` - FARE Peanut SLIT and Early Tolerance Induction	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.